Stockscreener 앱 받기
5.79
1.22%
0.07
시간 외 거래:
5.79
Nuvation Bio Inc 주식(NUVB)의 최신 뉴스
Forecasting The Future: 9 Analyst Projections For Nuvation Bio - Benzinga
Nuvation Bio's (NUVB) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma - BioSpace
Nuvation Bio expands SIGMA trial to phase 3 for IDH1-mutant glioma - Investing.com Canada
Nuvation Bio announces pivotal global phase 3 Sigma trial (G203) for Safusidenib in IDH1-mutant glioma - marketscreener.com
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial for Safusidenib in IDH1-Mutant Glioma - Investing News Network
S P Trends: Is Nuvation Bio Inc stock undervalued right nowPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Nuvation Bio Inc. (NUVB) Stock Analysis: Exploring 111.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Nuvation Bio stock maintains Buy rating at B.Riley on Ibtrozi sales momentum - Investing.com Nigeria
Analyst Endorsements Of Ibtrozi Uptake Could Be A Game Changer For Nuvation Bio (NUVB) - Sahm
Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy (NYSE:NUVB) - Seeking Alpha
Assessing Nuvation Bio (NUVB) Valuation After Bullish Analyst Calls On Ibtrozi And mIDH1 Glioma Potential - Yahoo Finance
Turist Financial Remains a Buy on Nuvation Bio (NUVB) - Finviz
Truist Highlights Nuvation Bio’s (NUVB) Ibtrozi’s Robust Market Uptake and Lead Over Competitors - Insider Monkey
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Nuvation Bio price target raised to $13 from $11 at Truist - Yahoo Finance
Truist Securities raises Nuvation Bio stock price target to $13 on Ibtrozi uptake - Investing.com Nigeria
Nuvation Bio Inc. (NUVB) price target lowered as IBTROZI sales meet expectations - MSN
Is Nuvation Bio Inc. stock undervalued right now2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - mfd.ru
Assessing Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Partnership Announcement - Sahm
JonesTrading Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - 富途资讯
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nuvation Bio Inc. (NUVB) Stock Analysis: 97% Potential Upside with Promising Oncology Pipeline - DirectorsTalk Interviews
Nuvation Bio (NYSE:NUVB) Stock Price Down 4.2%Here's Why - MarketBeat
Why Nuvation Bio (NUVB) Is Down 8.2% After Expanding Global Taletrectinib Partnership With Eisai - simplywall.st
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Yahoo Finance
Top 10 Oncology Stocks to Buy Now - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
10 Stocks Under $10 with High Potential - Insider Monkey
Aug Closing: Whats the analyst consensus on Surrozen IncLong Setup & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
A Look At Nuvation Bio’s Valuation After The Eisai Taletrectinib Collaboration Agreement - Sahm
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com Nigeria
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study By Investing.com - Investing.com Australia
1.24%
0.19%
자본화:
|
볼륨(24시간):